Wealth Enhancement Advisory Services LLC Boosts Stake in West Pharmaceutical Services, Inc. $WST

Wealth Enhancement Advisory Services LLC lifted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 9.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 29,173 shares of the medical instruments supplier’s stock after buying an additional 2,621 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in West Pharmaceutical Services were worth $7,759,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Generation Investment Management LLP purchased a new stake in West Pharmaceutical Services in the second quarter worth $255,072,000. Norges Bank purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $200,813,000. ProShare Advisors LLC lifted its holdings in West Pharmaceutical Services by 46.8% during the 2nd quarter. ProShare Advisors LLC now owns 738,368 shares of the medical instruments supplier’s stock valued at $161,555,000 after buying an additional 235,272 shares in the last quarter. Amundi boosted its position in West Pharmaceutical Services by 83.4% in the 2nd quarter. Amundi now owns 502,831 shares of the medical instruments supplier’s stock valued at $111,236,000 after buying an additional 228,696 shares during the period. Finally, Qube Research & Technologies Ltd bought a new position in West Pharmaceutical Services in the 2nd quarter worth about $30,592,000. 93.90% of the stock is owned by institutional investors.

Key West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Citi initiated coverage with a Buy, providing an independent institutional endorsement that can support demand for the shares and reinforce confidence in West’s strategic positioning. West Pharmaceutical Services (WST) Gets a Buy from Citi
• Positive Sentiment: Zacks Research upgraded WST to a Strong-Buy (Zacks Rank #1) and raised earnings estimates across multiple quarters and fiscal years, signaling improved analyst expectations for revenue/profitability and providing a near-term catalyst for buy-side interest. All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy
• Positive Sentiment: Product launch: West unveiled the Synchrony S1 prefillable syringe at Pharmapack 2026 — a move that targets biologics, vaccines and home-care use and could expand its addressable market in combination products and drug-delivery systems. WST Launches Synchrony S1 Prefillable Syringe at Pharmapack
• Neutral Sentiment: Analysis piece discusses West’s expansion into biologic syringe systems and whether that reshapes its combination‑product competitive edge — useful context for investors assessing long‑term growth but not an immediate earnings surprise. Does West Pharmaceutical (WST) Expanding Into Biologic Syringe Systems Reshape Its Combination-Product Edge?
• Neutral Sentiment: Zacks included WST on thematic lists (top medical-supply names and income-stock lists) — a visibility boost that may attract income and thematic investors but is less of an immediate price catalyst than upgrades or product news. 4 Medical Supply Stocks Poised to Gain

Wall Street Analyst Weigh In

WST has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft set a $345.00 price target on West Pharmaceutical Services and gave the company a “buy” rating in a report on Friday, October 24th. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday. TD Cowen assumed coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Finally, Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $335.78.

West Pharmaceutical Services Price Performance

Shares of WST stock opened at $236.78 on Friday. The company has a market cap of $17.03 billion, a P/E ratio of 35.08, a PEG ratio of 3.26 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The stock’s 50-day moving average is $270.73 and its 200 day moving average is $260.87. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $348.90.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. The business had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The company’s revenue was up 7.7% compared to the same quarter last year. During the same period last year, the business earned $1.85 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is presently 13.04%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.